Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …

Glioblastoma (GBM) is a particularly aggressive brain cancer associated with high
recurrence and poor prognosis. The standard of care, surgical resection followed by …

In patients with glioblastoma, resistance to the chemotherapeutic temozolomide (TMZ) limits
any survival benefits conferred by the drug. Here we show that the convection-enhanced …

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with an extremely low
survival rate. New and effective approaches for treatment are therefore urgently needed …

Mass spectrometry imaging (MSI) is an emerging technology that holds potential for
improving, biomarker discovery, metabolomics research, pharmaceutical applications and …

Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain
barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid …

Introduction: Acridine orange (AO) was first extracted from coal tar in the late nineteenth
century and was used as a fluorescent dye. In this paper, we review emergent research …

Pharmacometrics is a multidisciplinary field utilizing mathematical models of physiology,
pharmacology, and disease to describe and quantify the interactions between medication …

The poor transport of molecular and nanoscale agents through the blood–brain barrier
together with tumour heterogeneity contribute to the dismal prognosis in patients with …

Glioblastoma (GBM) is increasingly recognized as a disease involving dysfunctional cellular
metabolism. GBMs are known to be complex heterogeneous systems containing multiple …